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Platform technologies for measurement of CpGmethylation at multiple loci across the genome havemade am-
bitiousepigenome-wideassociationstudiesaffordableandpracticable. Incontrast togeneticstudies,whiches-
timate the effects of structural changes in DNA, and transcriptomic studies, which measure genomic outputs,
epigenetic studies can access states of regulationof genome function in particular cells and in response to spe-
cific stimuli. Althoughmany factors complicate the interpretationof epigenetic variation in humandisease, cell-
specificmethylation patterns and the cellular heterogeneity present in peripheral blood and tissue biopsies are
anticipated to cause themost problems. In this review, we suggest that the difficultiesmay be exaggerated and
weexplorehowcellularheterogeneitymaybeembracedwithappropriate studydesignsandanalytical tools.We
further suggest that systematicmappingof the loci influencedbyage, sexandgeneticpolymorphismswill bring
important biological insights as well as improved control of epigenome-wide association studies.
INTRODUCTION
Epigenetics broadlydefines the studyof changes that affectDNA
functionwithout altering the nucleotide sequence. Epigenetics is
nowahot area inmedical genomics. Large-scale projects such as
the International Human EpigenomeConsortium (http://ihec-ep
igenomes.org/) are generating comprehensive measurements of
the variation inDNAmethylation, histonemodification, nucleo-
some occupancy and coding and non-coding RNA expression
from normal and diseased cells. These data intersect with the
ENCyclopedia Of DNA Elements (ENCODE) project that is
building a comprehensive list of the functional elements of
the human genome by studying .4000 different datasets
covering a wide range of cells, conditions and technologies
(http://genome.ucsc.edu/ENCODE/index.html).
These resources offer wonderful opportunities for under-
standing and mapping genome function in health and disease.
Although there are many epigenetic markers that may be of
use in systematic studies, the degree of CpGmethylation at mul-
tiple sites (loci) across the genome is at the moment most easily
applicable to understanding disease. Hypermethylation in regu-
latory regions such as CpG islands, which are often associated
with transcription start sites, are generally associated with
genes that are not expressed, although other CpG sites in untran-
scribed genes may exhibit hypomethylation (1).
It is not yet clear to what extent methylation in regulatory
regions of genes is directly modifying gene expression or func-
tion and howmuch is the consequence of the binding of classical
transcription and enhancer factors. Nevertheless, it is generally
true that genome-wide methylation assays capture robust bio-
logical information about the functional state of cells and
tissues. It is reasonable to expect that this information can be
used to detect novel genes and pathways underlying disease
and to develop systematic understanding of essential processes
such as inflammation and repair.
The effective use of genome-wide data of this extent and com-
plexity is however demanding. Known but relatively uncharted
effects on epigeneticmarks atmultiple sites include age, sex, the
environment and DNA variants such as Single Nucleotide Poly-
morphisms (SNPs). Investigators will also have to deal with
batch effects that may arise from the platforms used to quantify
epigenetic variation.
Acurrentperception is that themajor problemwithepigenome-
wide studies arises because epigenetic changes determine
(or reflect) cellular differentiation into specific lineages (2–4),
requiring purified cells to be studied (5) or that the cell-specific
∗Towhomcorrespondence should be addressed at: ImperialCollegeLondon,GuyScaddingBuilding,RoyalBromptonCampus,DovehouseStreet, London
SW3 6LY, UK. Tel: +44 2075942943; Email: w.cookson@imperial.ac.uk
# The Author 2014. Published by Oxford University Press.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/ .0/),
which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
Human Molecular Genetics, 2014, Vol. 23, Review Issue 1 R83–R88
doi:10.1093/hmg/ddu284
Advance Access published on June 13, 2014
4
patterns be evaluated before attempting association studies (6).
If true, given that most tissues are complex mixtures of different
cells in varying stages of activity, then progress will be slow.
Happily, there are ways to deal with cellular heterogeneity that
do not involve exhaustive isolation of every cell type.
The main purpose of this review is to explore practical and
analytical approaches to CpG methylation that may be used to
control for cellular mixtures, whilst taking into account other
major potential confounders of epigenome-wide surveys.
EXPERIMENTAL DESIGN: EXERCISING
THE GENOME
A full discussion of experimental design is beyond the remit
of this review, but the concept of expression space of an individ-
ual genome is worth considering in strategies to extract the
maximum information from any study (7). The expression
space (or the epigenomic space) of a genome represents the
spectrum of various functions that the genome may carry out.
Exercising the genome captures states that are relevant to the
question under study. Experiments that exercise the epigenome
may examine the genome at different points in time after a
stimulus, or at different concentrationsof a stimulus (andconsid-
eringwhether the stimulus is physiological or pharmacological),
or testing in different subjects with different genetic and epi-
genetic backgrounds and examining genome function in
different cells and tissues (7). To this list can be added environ-
mental and disease-related stimuli that may strongly influence
the epigenome.
Most epigenome-wide association studies will be based on
a cross-sectional observational design that is similar to that
applied to genetic association studies. However, even this sim-
ple structure may draw on the epigenomic space in unexpected
ways.
Whilst DNA sequence changes are stable over the lifetime of
an individual, epigenetic changes may represent dynamic
responses to known and unknown confounding factors, such as
age, sex, the environment anddisease thatmayneed tobe consid-
ered in study design.
If these factors confound the outcome or exposure of interest
in a cross-sectional study, they can inflate false-positive rates as
well as reduce statistical power to capture real associations. In
common with gene expression studies and expression quantita-
tive loci (eQTL) mapping, it may be anticipated that statistical
power will be increased by modelling unknown as well as
known factors in association studies (8). We consider these
below.
BATCH AND PLATFORM EFFECTS
The technology for genome-wide measures of CpGmethylation
is steadily evolving. Illumina provides a popular platform for the
robust measurement of methylation status at 450 000 CpG resi-
dues across the genome, with matching probes comparing
sequences for native DNA compared with sequences after bisul-
phite conversion. This technology is likely to be replaced by
whole-genome bisulphite sequencing, with or without a means
for enriching for loci showing significant variation between
cells, tissues and individuals (9) [it is worth noting that other
cytosine modifications such as 5-hydroxymethylcytosine and
5-formylcytosine are found in genomic DNA of a wide range
of mammalian cells and may carry additional information
(10)]. The outcomeof thesemeasurements is a quantitative par-
ameter that captures the degree of methylation at a particular
site [in the case of Illumina platform, the parameter is b, mea-
sured on a scale of 0 (completely unmethylated) to 1 (completely
methylated)].
As with any microarray platform that measures quantitative
traits, batch effects, such as those associated with chips, plates,
runs, time and other experimental and biological conditions,
are expected to cause a large variation in parameter measure-
ment. Adjusting effectively for these can increase power and
reduce false positives.Adjustment canbe accomplishedby treat-
ing batch ID as a factor variable included as a fixed effect in the
regression model to test association. When the sample size is
small, an empirical Bayes method can be used to estimate
batch effects jointly using all probes on the array (11). An alter-
native is to model the batch ID as a random intercept in the
regression model, saving degrees of freedom and potentially in-
creasing power.
Confounding factors such as environmental exposures and
technical variations may commonly be represented in the array
data without being known or observable. High dimension
methods such as principal component analyses (PCA) andmulti-
dimensional scaling (MDS) can be used effectively to estimate
and adjust for such factors when they are sufficiently strong
(12,13). Similar adjustments have provided marked improve-
ments in power to detect eQTL associations in genome-wide
surveys (8,14).
AGE AND SEX
The age of subjects is known to influence methylation at
loci across the genome. Although monozygotic twins may be
indistinguishable by methylation status at birth, consistent
age-related changes (both negative and positive) may be
detected as children grow older (15). Gene ontology analyses
indicate that these loci affect genes for developmental processes
and immune functions and that there is overlap with loci that
change with age in adult studies (15). In healthy adults (post-
menopausal women), most age-related changes involve locus
hypermethylation and are not associated with the disabilities
that variably accompany ageing (16).
In contrast, other studies of adults suggest enrichment for struc-
turalmotifs such as bivalent chromatin domains in age-associated
DNA hypermethylation (17) and that these changes are not
immune or haemopoietic cell-type specific (17). It has also been
suggested that polycomb group proteins, which are supressed in
stem cells, may show increased methylation in post-menopausal
women, predisposing to malignancy (18). Other authors have
opined that genome-wide methylation profiles may be usefully
employed to quantify human rates of aging (19).
These papers reflect different schools of interpretation of
genome-wide methylation signals, the best of which aims for
reproducibility, meta-analyses, and mapped and confirmed loci
that eventually can be functionally interrogated. Importantly, at
least some of the age-related changes in methylation at specific
loci may be attributed with varying composition of different
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white cells in the peripheral blood leukocytes (PBLs) that are the
source of DNA for many genetic and epigenetic association
studies (20). These difficulties arising from cellular heterogen-
eity are discussed in detail below.
The effects of sex on methylation status are well documented
(21,22), beginning with the recognition that X-chromosome
inactivation in females is accompanied by widespread CpG
hypermethylation (23). Interestingly, the pattern of genes show-
ing methylation on the X chromosome is tightly regulated and
variable between individuals (24) may even be tissue specific
(25). Sex-related changes in methylation are also recognized at
autosomal loci (21,22), but these effects have not yet been sys-
tematically mapped or studied. A further complexity arises
from the recognition that environmental effects may produce
different methylation consequences in males and females, for
example genes influencing glucosemetabolism, obesity and dia-
betes amongst neonates in rural Gambia (26).
GENETIC POLYMORPHISM
Genetic polymorphisms such as SNPs are recognized to affect
methylation at individual loci (27) and genome wide (28,29).
These effects are strongest in cis but are also present in trans.
The mechanisms for SNP effects are not well understood but
are likely to relate to allelic differences in the binding or expres-
sion of regulatory factors, including non-coding RNAs.
True SNP effects need to be differentiated from genetic var-
iants that underlie themethylation probe sequence or theCpG in-
terrogation site. These polymorphisms can cause confounding
between methylation and the outcome of interest, as the per-
ceived association with methylation is in fact the association
with genotypes of the genetic variant. Such methylation probes
are easily removed during quality control steps of analysis.
Genetic variants may confound associations even when the
probe sequence or the CpG site does not overlap with any poly-
morphism. A genetic variant can be a regulator of the disease
outcome at the same time as influencing methylation at a CpG
site. In this case, association between outcome and methylation
reflects sharing of genetic controls rather than causality. One can
use mediation analysis (30–33) to estimate how much SNP–
outcome association is through methylation as an intermediate
phenotype and Mendelian randomization (34) to assess the
causal direction between SNP, methylation and outcome.
CELL-SPECIFIC EFFECTS
Lineage commitment to particular cell types can be identified by
methylation status at specific loci (2–4). There has been consid-
erable concern that studying heterogeneous mixtures of cells
from tissues andperipheral bloodwill cause serious confounding
of epigenome-wide association studies (5,6) and that as a
consequence purified cells should be studied (5) or that the cell-
specific pattern for the gene region of interest should be evalu-
ated before attempting association studies (6).
If this assumption is correct, then larger-scale epigenome
studies will prove very technically difficult to perform. It is
worth observing that cell specificity applies equally to studies
of global gene expression, and, despite the old canard that
gene expression in peripheral blood measured by microarrays
was really an expensive cell count, there have been enormous
advances in mapping eQTLs from lymphoblastoid cell lines
and tissues with heterogeneous composition (8,35,36). Such
studies have been particularly helpful in understanding system-
atically the function of the numerous disease-associated loci dis-
covered by genome-wide association studies (GWAS) (35).
Before exploringmeansof resolvingor controlling for cellular
heterogeneity, there are two further complicating factors that are
not usually considered. First, not all PBL constituents will be
treated equally by the process of DNA extraction: buffy coats
are retrieved after centrifugation that separates some granulo-
cytes (such as eosinophils and basophils) from lymphocytes,
monocytes and neutrophils, and red cell lysis methods may
have differential effects on monocytes compared with other
PBLs. It is therefore essential that cases and controls in a study
have DNA extracted by matching protocols and that the results
from different subjects and panels are amalgamated by
meta-analyses rather than simple pooling.
Secondly, and equally of relevance, most PBLs exist in acti-
vated and unactivated states, including neutrophils (37), eosino-
phils (38,39), monocyte–macrophages (40) and T cells and
B cells (41). Based on knowledge of gene expression, activation
will in each case be accompanied by important changes in
methylation profiles (Fig. 1). The manipulation of cells during
their purification may also perturb their methylation profile
and gene expression. In these circumstances, simplistic isolation
of pure cell types and their use as references may generate add-
itional ungovernable influences on study outcomes.
Will it then be possible to detectmeaningful associations from
unfractionated cells? Assuming experimental variables (ances-
try, DNA extraction methods, batch and platform effects) are
controlled, then the power to detect cell-specific associations
from PBLs and other tissues will depend on the proportion of
each cell type, the effect size in specific cells and the sample
size (Fig. 1). Assuming the variance at a locus arises from a
particular cell type in a sample, then the overall variance in
DNA from PBL or a tissue will produce an attenuation of
the effect size in specific cells that would mask associations
rather than magnify them. Similarly, the study of the wrong cell
types (such as in some circumstances, the Epstein–Barr virus-
transformed lymphoblastoid cell lines that are commonly used
as a renewable source of DNA for genetic studies) will produce
null results rather than systematic false positives.
Pushingonand ignoringheterogeneity for themoment, a posi-
tive association resultmay then be entirely due to the presence of
particular cells or to the activation of particular cells, or as is
perhaps most likely, a combination of these effects (Fig. 1)
(it is also quite conceivable that the effects may be general and
not cell specific at all). These primary results may themselves
be of interest, such as the highly reproducible effects of cigarette
smoking on genes potentially affecting coagulation pathways
(42,43), but a general next step becomes to engage cellular het-
erogeneity and to differentiate between possibilities.
Although whole blood is often the only available tissue in
large-scale epidemiology studies, it is fortunate that phenotyp-
ing of subjects often includes full blood counts (FBCs, also com-
plete blood counts), which are routinely measured by clinically
standardized automated procedures. The FBC gives absolute
counts and proportions of all major constituents of PBL, with
high reproducibility and well-understood normal values.
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To account for cellular heterogeneity in epigenetic associ-
ation studies, one commonly used approach is to include these
white cell counts (or their proportions) as fixed effects in regres-
sionmodels (44). These factors are often included as linear terms
in the regression model and can adjust for confounding in most
situations, although non-linear effects from cell counts should
be considered when examining interactions (45).
In the absence of an FBC, or for other factors that are known
but not observed, association models can in theory be built on
factors that are estimated from known methylation patterns in
particular cell types such as CD8+, CD4+ and natural killer T
cells, based on a cell-sorted methylation data (5,20). These
achieve reliable estimates of fractions of major cell types in
tightly controlled experiments, but their practical utility may
be confounded by disease-relevant cellular activation in patients
and population samples (Fig. 1). Additionally, reference panels
based on sorted cells are not available from important sources
such as adipose or tumour tissue.
In the absence of reference data, major components in
genome-wide DNA methylation patterns from PBL can be esti-
mated and used as surrogates of cell proportions (46,47), even to
the suggested extent that it may be helpful in non-hematopoietic
cancers (48).
Strong associations between methylation and exposure or
outcome should be taken into accountwhen estimating surrogate
components, using analyses such as those implemented in
RefFreeEWAS (49), surrogate variable analysis (50) in SVA
(12) or SVA-PLS (51) and the Bayesian factor analysis
package PEER (13,52). Surrogate components, estimated expli-
citly with PCA or MDS or implicitly using linear mixed models
such asEWASher (53),may lose power to detect true association
with large effect sizes but are of most use when effect size is
smaller than confounding factors (8,14). Genomic control
remains a final approach to correct for systematic inflation in
false positives in an association study (54).
A further approach to detecting for cell-specific effects may
lie in network analyses, which can identify co-regulated gene
modules that represent functional biological units of a system
(55). Correlation-based networks discovered through the
WCGNA package (56) have previously been shown to strongly
correlate with particular cell types using global gene expression
(57,58) as well as global CpG methylation patterns (59).
Whilst certainly helpful, it is likely that the statistical infer-
ences described earlier will never be better than direct cell
counts, and any models incorporating measured or imputed
cell counts may never be completely convincing, at least to
referees.
For epigenetic associations to be substantiated, the onus
still falls on validation of primary associations in secondary
panels of subjects, ideally followed by the demonstration of
effects in isolated cells from cases and controls. In understand-
ing the functional consequences of epigenetic associations,
Figure1.Cellular heterogeneity and epigenetic association. The toppanel of thefigure showshow two types of cells (A andB)maybe indifferent proportions in tissue
samples from cases (for example, A4 : B5) and controls (A2 : B7). If epigenetic variation between cases and controls is confined to these cells, then their proportions
(shown inblue)will be reflected in their epigenetic ratios (shown inpurple:q indicates thenumberof cells that arequiescent).This doesnot, however, render the results
of association testing unimportant. The lower panel illustrates the case when cell type A and cell type B are capable of quiescent and active states (as, for example, is
usual for immunological cells).Here, simple cell countswillmiss significant alterations in the epigenetic profileof cell typeB (shown inpurple:q indicates the number
of cells that are quiescent and a the number that are active). In both examples, themeasure of epigenetic changes provides an accurate estimate of differences between
case and control samples.
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it may become important to appreciate that methylation shows
a complex and currently unpredictable relationship to gene
expression (60).
CONCLUSIONS
The use of epigenome-wide information in association with
other studies is therefore far from facile. In addition to effects
of age, sex, genetic polymorphism, cellular heterogeneity and
the environment are added DNA extraction methods, batch
effects and the recognition that activated immune, and other
cells exhibit a very different epigenotype to their resting name-
sakes. Nevertheless, these obstacles are surmountable with
appropriate study designs and analytical tools. We believe that
systematic mapping of loci influenced by age, sex and SNPs
will allow direct control of their influence in future studies, as
well as examining important biological processes.
Finally, it should be realized that dynamic epigenetic changes
may follow rather than initiate disease processes, so that associ-
ation with epigenetic variation may not indicate causality in the
same way as an SNP association. Nevertheless, epigenomics
provides the opportunity for remarkable insights into genome
function. Global gene expression is of proven value in interpret-
ing the functional consequence of disease associations (36), but
its measurement is expensive and requires stringent sample col-
lection and storage. In contrast, DNA from PBL is often avail-
able from historic population and case–control studies, so that
genome-wide mapping of CpG methylation may directly
inform on mechanisms of diverse diseases, even from DNA
that is 30 000 years old (61).
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